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Background: As the multipotent progenitor population of the airway epithelium, human airway basal cells (BC) replenish
the specialized differentiated cell populations of the mucociliated airway epithelium during physiological turnover and
repair. Cultured primary BC divide a limited number of times before entering a state of replicative senescence, preventing
the establishment of long-term replicating cultures of airway BC that maintain their original phenotype.
Methods: To generate an immortalized human airway BC cell line, primary human airway BC obtained by brushing the
airway epithelium of healthy nonsmokers were infected with a retrovirus expressing human telomerase (hTERT). The
resulting immortalized cell line was then characterized under non-differentiating and differentiating air-liquid interface
(ALI) culture conditions using ELISA, TaqMan quantitative PCR, Western analysis, and immunofluorescent and
immunohistochemical staining analysis for cell type specific markers. In addition, the ability of the cell line to respond
to environmental stimuli under differentiating ALI culture was assessed.
Results: We successfully generated an immortalized human airway BC cell line termed BCi-NS1 via expression of hTERT.
A single cell derived clone from the parental BCi-NS1 cells, BCi-NS1.1, retains characteristics of the original primary cells
for over 40 passages and demonstrates a multipotent differentiation capacity into secretory (MUC5AC, MUC5B), goblet
(TFF3), Clara (CC10) and ciliated (DNAI1, FOXJ1) cells on ALI culture. The cells can respond to external stimuli such as
IL-13, resulting in alteration of the normal differentiation process.
Conclusion: Development of immortalized human airway BC that retain multipotent differentiation capacity over
long-term culture should be useful in understanding the biology of BC, the response of BC to environmental stress,
and as a target for assessment of pharmacologic agents.
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The human airway epithelium, a complex pseudostratified
multicellular layer that lines the bronchial tree, is com-
prised of ciliated, secretory, intermediate/undifferentiated
and basal cells (BC) [1-3]. The BC, a proliferating popula-
tion of cells that reside in close proximity to the basement
membrane, function as stem/progenitor cells of both the
mouse and human airway epithelium and are capable of
differentiating into the other specialized cell types during* Correspondence: geneticmedicine@med.cornell.edu
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reproduction in any medium, provided the ornormal epithelial turnover and repair [4-18]. In re-
sponse to stress, such as cigarette smoke or inflamma-
tory stimuli, this differentiation process is altered,
resulting in a disordered airway epithelium [19-26]. Un-
derstanding the mechanisms by which the differenti-
ation capacity of the BC is regulated and how the cells
respond to specific environmental stimuli is central to
the understanding of diseases characterized by airway
epithelial remodeling such as chronic obstructive pul-
monary disease (COPD) and asthma, and the biology of
the malignant transformation of the epithelium into
bronchogenic carcinoma [3,8,26-30].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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way BC that maintain features of their original phenotype
would provide a convenient means to study the mecha-
nisms that regulate BC differentiation, assess the response
of BC to environmental stress and screen drugs targeted
toward suppressing or activating specific pathways. The
challenge in studying these processes is that, like all nor-
mal somatic cells, cultured primary human airway BC div-
ide only a limited number of times before entering a state
of replicative senescence. The short lifespan of primary
BC cultures, coupled with biological changes that occur as
cells reach senescence, limits the experimental scope for
which each culture can be utilized [31,32]. To address this
problem, various different strategies have been employed.
For instance, recent studies have demonstrated that
primary human epithelial cells (including human airway
epithelium) can be propagated indefinitely in vitro when
co-cultured with irradiated fibroblast feeder cells and a
Rho kinase inhibitor [33,34]. Prior studies have demon-
strated that long term cultures of human bronchial epithe-
lium obtained from bronchial derived donor material can
be established using a number of different methods, in-
cluding adenovirus-SV40 hybrid virus; plasmid containing
a replication defective SV40 virus genome; and plasmid or
retroviral gene transfer-mediated delivery of viral onco-
proteins (HPV-16 E6 and E7, or SV40 T-antigen) alone or
in combination with the catalytic subunit of human tel-
omerase reverse transcriptase (hTERT) [35-41]. Alterna-
tive strategies to viral oncoproteins have used retroviral
gene transfer-mediated expression of hTERT alone or to-
gether with cyclin dependent kinase 4 (CDK4) or B-cell
Moloney murine leukemia retrovirus-specific integration
site 1 (Bmi-1). Cells produced by these strategies have an
extended life span far beyond normal senescence and re-
tain characteristics of the primary cells [42-46].
Based on these observations, and utilizing methodology
in our laboratory to culture pure populations of human
airway BC from the airway epithelium obtained by brush-
ing the airway epithelium of healthy nonsmokers, we have
successfully immortalized a human airway BC cell line de-
rived from a healthy nonsmoker via retrovirus-mediated
expression of hTERT. The resulting cell line, termed basal
cell immortalized-nonsmoker 1 (BCi-NS1), and a clonal
population of the parental cells (BCi-NS1.1) retain charac-
teristics of the original primary cells, maintain a multipo-
tent differentiation capacity for over 40 passages and
respond to external stimuli to alter the normal differenti-
ation process.
Methods
Sampling airway epithelium and culture of primary
human airway basal cells
Under a protocol approved by the Weill Cornell Medical
College Institutional Review Board, healthy nonsmokerswere recruited for this study. The subjects were con-
firmed to be nonsmokers by urine levels of nicotine
(<2 ng/ml) and cotinine (<5 ng/ml) with normal pul-
monary function tests and chest X-ray. Following written
informed consent, flexible bronchoscopy was used to
collect large airway epithelial cells by brushing the epi-
thelium [47-49]. Basal cells (BC) were subsequently puri-
fied from the total airway epithelium brushings by
trypsinization of the cells and selective culturing of BC
on T25 cm2 plastic tissue culture flasks as previously de-
scribed [4,50]. The airway epithelial cells collected
by brushing were pelleted by centrifugation (250 × g,
5 min) and disaggregated by resuspension in 0.05% trypsin-
ethylenediaminetetraacetic acid (EDTA) for 5 min, at 37°C.
Trypsinization was stopped by addition of HEPES buffered
saline, (Lonza, Basel, Switzerland) supplemented with 15%
fetal bovine serum (FBS; GIBCO-Invitrogen, Carlsbad, CA),
and the cells were again pelleted at 250 × g, 5 min. The pel-
let was resuspended with 5 ml of phosphate buffered saline,
pH 7.4 (PBS), at 23°C, then centrifuged at 250 × g, 5 min.
Following centrifugation, the PBS was removed and the
cells resuspended in 5 ml of Bronchial Epithelial Growth
Media (BEGM, Lonza, CA) and 5 × 105 cells plated in T25
flasks in 5 ml of BEGM and maintained in a humidified at-
mosphere of 5% CO2 at 37°C. The next day, unattached
cells were removed by changing the medium and thereafter,
every 2 days. Following 7–8 days of culture, when the
cells were 70% confluent, they were characterized by
immunohistochemical staining of tryspinized cytopreps
using cell type specific markers as being >99% BC
(KRT5+, TP63+, CD151+, β-tubulin IV-, MUC5AC-,
TFF3-, CC10-, chromogranin A- and N-cadherin-) and
when put on air-liquid interface (ALI) culture, were
capable of differentiating into a mucociliary epithelium
[4]. To passage the cells, the primary BC were seeded at
a cell density of 3000 cells/cm2 in BEGM. The following
day, the media was replaced with fresh BEGM and
thereafter, every 2 days.
Generation of an hTERT expressing retrovirus
Human telomerase (hTERT) was PCR amplified with for-
ward (5′-CGATCGATGCCACCATGCCGCGAGCTCC
CCGTTGCCGAG-3′) and reverse (5′- GGTACGTATC
AGTCCAGGATGGTCTTGAAGTCTG-3′) primers and
cloned into the TOPO® TA subcloning vector (Invitrogen,
Carlsbad, CA) using the manufacturer’s protocol. The
hTERT insert was then subcloned into the pBABE-
puromycin retroviral vector [51] via the EcoRI restriction
site. The resulting plasmid pBABE-puro-hTERT was se-
quenced to verify the correct orientation and integrity of
the hTERT open reading frame. Recombinant replication
deficient retroviruses were generated by transient co-
transfection of 293A cells with pBABE-puro-hTERT and
the packaging plasmids pGAG-Pol and pMD.G (VSVg
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24 hr intervals with replacement of fresh media at each
time point. At 72 hr post transfection, the media was har-
vested and pooled with previous time points for subse-
quent virus purification by standard methods.
Immortalization of human airway basal cells
Cultured primary airway BC from a 42 yr old Hispanic,
male, healthy nonsmoker were immortalized using
retrovirus-mediated expression of hTERT. The primary
BC were passaged once and subsequently seeded at a
density of 105/cm2 into each well of a 6-well plate in
BEGM. The following day, the media was replaced and
24 hr later the cells infected overnight with the retrovirus
expressing hTERT and the puromycin resistance selection
marker in the presence of polybrene (2 μg/ml). The next
day, the cells were washed with PBS and then incubated
for 3 days in BEGM. After 3 days, selection media (BEGM
containing 0.5 μg/ml of puromycin) was added for 10 days.
As a control to demonstrate the activity and killing effect
of the puromycin, uninfected BC (non-puromycin resist-
ant) were treated simultaneously. Once selection of resist-
ant cells was complete, the cells were cultured in BEGM
(minus puromycin) in the same way as primary BC. This
parental immortalized cell line was termed basal cell
immortalized-nonsmoker 1 (BCi-NS1). A clonal popula-
tion of immortalized BC (BCi-NS1.1) was generated by
serial dilution of the parental cells and subsequent expan-
sion of isolated single cell colonies. Based on the findings
of previous studies that immortalization of primary hu-
man airway epithelium with hTERT alone is either ineffi-
cient or requires additional genes to extend the lifespan of
cells beyond 30 passages (Additional file 1: Table S1), we
used the criteria of lifespans greater than 40 passages to
deem the cells immortalized. The immortalized BC were
cultured in an identical manner to primary BC and seeded
at a cell density of 3000 cells/cm2 in BEGM for all experi-
ments unless stated otherwise.
Measurement of telomerase activity
Telomerase activity was measured by the PCR-based Telo-
meric Repeat Amplification Protocol (TRAP) according to
the manufacturer’s instructions (TRAPeze® Telomerase De-
tection Kit; Cat# S7700; Millipore, Billerica, MA). Briefly,
cell lysates from the parental primary BC and immortalized
BCi-NS1 cells were generated and an equal amount of total
protein (2 ug) added to each reaction. A telomerase positive
HeLa cell extract provided with the TRAPeze® kit was used
as a positive control and heat inactivation of the same
extract was used as a negative control. Following PCR
amplification, the Cy5-labeled products were resolved on
a polyacrylamide gel and visualized using a Molecular
Dynamics Typhoon Trio + (GE Healthcare Biosciences,
Pittsburgh, PA) to determine telomerase activity.Characterization of human airway basal cells
The primary donor, immortalized parental BC and the
BCi-NS1.1 clone were characterized by expression of cell
type specific markers using previously described methods
[4,50]. Cytospin slides of trypsinized cultured BC were pre-
pared for characterization by immunohistochemistry
(described below), using the following cell-type specific
markers: KRT5 (basal cell); TP63 (basal cell); CD151 (basal
cell); β-tubulin IV (ciliated cell); MUC5AC (secretory cell);
TFF3 (goblet cell); CC10 (Clara cell); chromogranin A
(neuroendocrine cell); and N-cadherin (mesenchymal cell).
Only cultures >99% positive for basal cell markers and
negative for other cell types were used in this study. Karyo-
type analysis of the immortalized cells was performed at
the Molecular Cytogenetics-Core Facility at Memorial
Sloan-Kettering Cancer Center using established protocols
(http://www.mskcc.org/research/molecular-cytogenetics).
At least 17 metaphase spreads were analyzed for each pas-
sage of BCi-NS1.1 cells.
Western analysis
Cells were harvested and lysed in radioimmunoprecipita-
tion lysis (RIPA) buffer (Sigma, St. Louis, MO) containing
complete protease inhibitor cocktail (Roche, Mannheim,
Germany) and halt phosphatase inhibitor cocktail (Pierce,
Rockford, IL). The protein concentration was then quanti-
fied using the Bradford Assay and an appropriate volume
of 4X NuPAGE LDS sample buffer (Invitrogen) containing
200 mM dithiothreitol (DTT) added to each sample. The
cellular lysates were then boiled for 10 min and equal
amounts of total protein for each sample analyzed using
NuPAGE 4–12% Bis–Tris gradient gels (Invitrogen) and
subsequently transferred onto nitrocellulose membranes
with a Bio-Rad semidry apparatus before Western analysis.
The membranes were then blocked overnight at 4°C in 4%
blocking reagent (Nonfat milk) made in PBS containing
0.1% Tween-20 (PBST). After blocking the membranes
overnight, immobilized proteins were reacted with the fol-
lowing cell-type-specific antibodies in 4% blocking reagent
for 1 hr, 25°C with shaking: KRT5 (basal cell; 1/5000; PA1-
37974; Thermo Scientific, Rockford, IL); TP63 (basal cell;
1/3000; sc-8431; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA); MUC5AC (secretory cell; 1/500; VP-M657;
Vector Laboratories, Burlingame, CA); CC10 (Clara cell;
1/10000; RD181022220; BioVendor LLC, Candler, NC);
DNAI1 (ciliated; 1/2000; HPA021649; Sigma); FOXJ1
(ciliated; 1/1000; 14–9965; eBioscience, San Diego, CA);
and GAPDH (loading control; 1/10000; sc-32233; Santa
Cruz Biotechnology, Inc). Following the primary antibody
incubation, membranes were washed three times for 5 min
each with PBST, followed by incubation with an anti-rabbit
or anti-mouse antibody conjugated to horseradish peroxid-
ase in 4% blocking reagent for 1 hr at room temperature
with shaking. On completion of the secondary antibody
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three times for 5 min with PBST and twice with PBS,
and antibodies visualized after the addition of ECL
Western analysis detection reagents (GE Healthcare
Biosciences) by exposure to X-ray film. For Western
analysis of ALI experiments, the cells were lysed directly
in ALI Transwell inserts using 100 μl of 1 × NuPAGE
LDS sample buffer (Invitrogen) diluted in radioimmu-
noprecipitation lysis (RIPA) buffer (Sigma) containing
complete protease inhibitor cocktail (Roche), halt phos-
phatase inhibitor cocktail (Pierce) and 50 mM dithio-
threitol (DTT). The lysates were then boiled for 10 min
and equal volumes of each sample analyzed using
NuPAGE 4–12% Bis–Tris gradient gels (Invitrogen) and
subsequently processed as described above.Immunohistochemistry
For characterization of BC cultures by immunohisto-
chemistry, cytospin slides of trypsinized cells were pre-
pared, and subsequently fixed in 4% paraformaldehyde
for 15 min. An antigen recovery step was carried out
by steaming the samples for 15 min in citrate buffer so-
lution (Thermo Scientific), followed by cooling at 23°C
for 20 min to enhance staining. Endogenous peroxid-
ase activity was quenched using 0.3% H2O2 for 30 min,
followed by incubation for 20 min with normal serum
matched to the secondary antibody to reduce back-
ground staining. Samples were incubated overnight at
4°C with the following primary antibodies: KRT5 (basal
cell; 1/500; PA1-37974; Thermo Scientific); TP63 (basal
cell; 1/200; sc-8431; Santa Cruz Biotechnology, Inc.);
CD151 (basal cell; 1/200; NCL-CD151; Leica Microsys-
tems, Inc., Bannockburn, IL); β-tubulin IV (ciliated cell; 1/
1000; MU178-UC; Biogenex, San Ramon, CA); MUC5AC
(secretory cell; 1/70; VP-M657; Vector Laboratories);
TFF3 (goblet cell; 1/200; 2816–1; Epitomics, Burlingame,
CA); CC10 (Clara cell; 1/10000; RD181022220; BioVendor
LLC); chromogranin A (neuroendocrine cell; 1/5000; MS-
382-P; Thermo Scientific); and N-cadherin (mesenchymal
cell; 1/500; 33–3900; Invitrogen). Isotype-matched IgG
(Jackson ImmunoResearch Laboratories Inc., West
Grove, PA) was used as a negative control. The Vectas-
tain Elite ABC kit and AEC substrate kit (Dako North
America Inc., Carpinteria, CA) were used to visualize
antibody binding and slides were counterstained with
Mayer’s hematoxylin (Polysciences Inc., Warrington,
PA) and mounted using faramount mounting medium
(Dako North America Inc.). Images were acquired using
a Nikon Microphot microscope with a Plan 60 × N.A.
0.70 oil immersion objective lens and an Olympus DP70
CCD camera. For all experiments, appropriate positive
control tissues were used to confirm specificity and
positive staining for each antibody.ELISA
The secretion of VEGFA by primary BC and BCi-
NS1.1 cells was assessed by ELISA (R&D Biosystems,
Minneapolis, MN). For each cell type, 105 cells were
seeded into each well of a 12-well plate in duplicate in
BEGM growth media. The next day, the cells were
washed one time with PBS and incubated for 24 hr in
1 ml BEGM. Following incubation, the media was re-
moved and then centrifuged at 250 × g, 5 min to pellet
cellular debris. The supernatant was then analyzed by
ELISA using the manufacturer’s instructions. Growth
media (BEGM) not exposed to BC and containing no
VEGFA was used as a negative control. For each sam-
ple, the final cell numbers following media harvest
were counted and used to calculate the levels of se-
creted VEGFA per cell. Final calculations of secreted
VEGFA for each sample represent an average of the
duplicate reactions. For primary BC, each independent
culture was passaged a maximum of three times before
ELISA analysis.
Endothelial Co-culture proliferation assays
Co-culture proliferation assays were used to assess the abil-
ity of endothelial cells to support primary BC and BCi-
NS1.1 proliferation in cytokine- and serum-free conditions
as previously described [50]. Briefly, HUVEC-Akt cells
(5 × 104) were seeded into each well of a 12-well plate in
HUVEC growth media. The next day the media was re-
moved and the cells washed twice with PBS, followed by
seeding 2 × 104 primary BC or BCi-NS1.1 cells into each
well in BEGM growth media. The next day (termed day 0)
the media was removed and the cells washed twice with
PBS before addition of cytokine- and serum-free BEBM
media. The cells were then incubated and subsequently
harvested and counted at the desired time points. As a con-
trol, primary BC or BCi-NS1.1 cells were seeded into wells
containing no HUVEC-Akt controls and subsequently
treated in an identical manner to those in co-culture. At
the desired time points, cells were trypsinized and total cell
numbers were measured with a hemocytometer and the
viability assessed by counting of trypan blue dye-excluded
cells. The population of GFP-labeled HUVEC-Akt cells in
the harvested sample was determined as the GFP+VE-cad-
herin+ population by flow cytometric analysis, and the GFP-
VE-cadherin- population quantified as expanded primary
BC or BCi-NS1.1 cells. For primary BC, each independent
culture was passaged one time to obtain sufficient cell ma-
terial before study in co-culture.
Air-liquid interface culture
To investigate the differentiation capacity of the immortal-
ized BC, the cells were grown on air-liquid interface (ALI)
cultures using established methods [4,50]. The immortal-
ized BC were trypsinized and then seeded at a density of
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pore; Corning Incorporated, NY) coated with human type
IV collagen (Sigma) in media consisting of a 1:1 mixture of
DMEM (Cellgro, Manassas, VA) and Ham’s F-12 Nutrient
Mix (Invitrogen) supplemented with 100 U/ml penicillin,
5% fetal bovine serum 100 μg/ml streptomycin, 0.1% gen-
tamycin and 0.5% amphotericin B. Following overnight in-
cubation, the media was replaced with 1:1 DMEM/Ham’s
F12 (including antibiotics described above) supplemented
with 2% of the serum substitute Ultroser G (BioSerpa S.A.,
Cergy-Saint-Christophe, France). Two days post seeding,
the media was removed from the upper chamber to
expose the apical surface to air and establish the ALI
(referred to as ALI day 0). The ALI cultures were then
grown at 37°C, 8% CO2, with fresh media changes every 2
to 3 days. Following 5 days on ALI, the CO2 levels were
reduced to 5% until harvest of the cultures at ALI day 28.
The transepithelial resistance (TER) was measured at each
media change using a Millicell-ERS epithelial ohm meter
(Millipore, Bedford, MA) and results plotted over the
course of time. For each time point and condition, the re-
sistance of 3 replicate ALI wells was assessed. For experi-
ments investigating the effect of IL-13 stimulation on
differentiation of the immortalized BC, the standard ALI
method was employed and 5 ng/ml of IL-13 (Peprotech,
Rocky Hill, NJ) added at ALI day 10 to the basolateral
media. The IL-13 stimulation was maintained until ALI
day 28 with fresh IL-13 added at each media change. Ex-
periments studying the differentiation of immortalized BC
were performed with cells grown between passages 6 to
43. For primary BC, each independent culture was pas-
saged one time to obtain sufficient cell material before
study on ALI. Histological analysis of ALI day 28 cultures
for both primary BC and BCi-NS1.1 cells was performed
via staining of paraffin embedded ALI sections. Briefly,
ALI day 28 transwell inserts were fixed directly with 4%
paraformaldehyde in PBS for 20 min and then shipped in
70% ethanol to Histoserv, Inc (Germantown, MD) where-
upon the membrane was removed from the transwell in-
sert and subsequently dehydrated through graded
alcohols, cleared in xylene and then infiltrated with low
melt temperature paraffin. Following processing, the cir-
cular membrane was bisected and both halves embedded
on the cut edge in the same paraffin block. Five micron
sections were then generated and mounted on slides for
subsequent analysis.
Immunofluorescence
Differentiation of primary and immortalized BC on ALI
culture was confirmed using immunofluorescent staining
of paraffin embedded cross-sections or directly by top-
staining of the ALI membrane. For analysis of paraffin
embedded sections, the samples were first cleaned in
xylene and rehydrated with graded ethanol. To unmaskthe antigens, samples were steamed for 15 min in citrate
buffer solution (Thermo Scientific), followed by cooling
at 23°C for 20 min, then blocked for 30 min with normal
serum to reduce background staining. For direct
top-staining, the ALI membranes were fixed directly
with 4% paraformaldehyde in PBS for 20 min and then
permeabilized with 0.1% triton X-100 in PBS, followed
by blocking with normal serum. The samples were then
treated and stained with the following primary anti-
bodies: KRT5 (basal cell; 1/100; PA1-37974; Thermo
Scientific); β-tubulin IV (ciliated cell; 1/100; MU178-UC;
Biogenex); CC10 (Clara cell; 1/200; RD181022220;
BioVendor LLC); MUC5AC (secretory cell; 1/50; VP-
M657; Vector Laboratories); and TFF3 (goblet cell; 1/
100; 2816–1; Epitomics) for 60 min at 23°C. Isotype
matched IgG (Jackson Immunoresearch Laboratories)
was the negative control. To visualize the antibody bind-
ing, Alexa Fluor® 488 Goat Anti-Mouse IgG (A-11029;
Invitrogen) and Alexa Fluor® 546 Goat Anti-Rabbit IgG
(A-11035; Invitrogen) labeled secondary antibodies were
used. The cells were counterstained with DAPI to iden-
tify cell nuclei and subsequently mounted using
ProLong® Gold antifade reagent (Invitrogen). For top-
staining, the ALI membrane was cut from the well
before mounting. Immunofluorescent microscopy was
performed using a Zeiss Axioplan body microscope with
either a 20 × or 40 × lens. The images were captured
with a Zeiss hrM (high resolution monochrome) camera.
Quantification of differentiation
To quantify the differentiation capacity of primary BC and
immortalized BC following ALI culture, paraffin-embedded
sections were stained with Alcian blue/Nuclear Fast Red
Kernechtrot Reagents (Cat# K066; Poly Scientific R&D
Corp., Bay Shore, NY) to determine the percentage of cili-
ated and secretory cells. A minimum of 10 images equally
distributed between both ends of the sectioned membrane
were acquired using a Nikon Microphot microscope with a
Plan 40 × N.A. 0.70 objective lens and an Olympus DP70
CCD camera. Ciliated cells were determined by morph-
ology and the number of secretory cells by Alcian blue
staining. For each sectioned membrane, a minimum of 250
total cells were counted.
TaqMan gene expression
Total RNA was extracted using a modified version of the
TRIzol method (Invitrogen), in which RNA is purified dir-
ectly from the aqueous phase using the Rneasy MinElute
RNA purification kit (Qiagen, Valencia, CA). RNA concen-
tration was determined using a NanoDrop ND-1000 spec-
trophotometer (NanoDrop Technologies, Wilmington,
DE) and cDNA synthesized from 1 μg of total RNA using
TaqMan Reverse Transcription Reagents (Applied Biosys-
tems, Foster City, CA). All samples were then analyzed in
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to ensure amplification efficiency of the reference gene and
gene of interest are consistent. All reactions were run on an
Applied Biosystems Sequence Detection System 7500 and
relative expression levels determined using the dCt method
with 18S ribosomal RNA as the endogenous control.
Premade TaqMan Gene Expression Assays were obtained
from Applied Biosystems: CLDN3 (Hs00265816_s1);
CLDN8 (Hs00273282_s1); KRT5 (Hs00361185_m1); TP63
(Hs00978343_m1); MUC5AC (Hs01365616_m1); MUC5B
(Hs00861588_m1); CC10 (SCGB1A1, Hs00171092_m1);
TFF3 (Hs00902278_m1); DNAI1 (Hs00201755_m1);
FOXJ1 (Hs00230964_m1); and 18S rRNA (TaqMan® Ribo-
somal RNA Control, VIC, #4308329). For each time point
and condition, gene expression levels in a minimum of 2
replicate ALI wells were assessed.
Scratch and wound healing assay
Air-liquid interface cultures of immortalized BCi-NS1.1
cells were set up as described above. At ALI day 0, follow-
ing exposure of the apical surface to air, a sterile P10 pip-
ette tip was used to scratch across the epithelial surface to
induce injury. The apical surface was then washed once
with PBS to remove the unattached cells from the injured
area, and the cells were subsequently incubated under
standard ALI culture conditions to assess the ability of the
cells to repair the injured region. Images were acquired at
the time of injury (t = 0) and following repair to document
the repair process. The procedure was repeated at add-
itional time points during ALI culture (ALI day 7, 14, 21
and 28).
Statistical analysis
All data included in this study are presented as the
average ± standard error. Statistical comparisons were
calculated using an unpaired, 2-tailed Student’s t test
with unequal variance. A p value <0.05 was considered
significant.
Results
Immortalization of primary human airway basal cells
To establish an immortalized human airway basal cell (BC)
cell line, primary airway BC were isolated with selective cul-
ture methods from the large airway epithelium of a male
healthy nonsmoker. The cells displayed a healthy cobble
stone morphology typical for airway BC (Figure 1A). In
contrast to the parental primary BC which reached senes-
cence following 5 passages (Figure 1B), the hTERT modi-
fied, puromycin resistant populations of BCi-NS1 cells
continued to proliferate and grow beyond 40 passages while
retaining a healthy morphology, demonstrating that ectopic
expression of hTERT was sufficient to extend the lifespan
of primary BC (Figure 1C). A telomeric repeat amplification
protocol (TRAP) assay confirmed telomerase activity withinthe BCi-NS1 cells. Analysis of cell lysates from the primary
BC demonstrated no hTERT activity and appeared iden-
tical to the negative control (Figure 1D, lanes 1, 4). In
contrast, the cell lysates from the BCi-NS1 cells were
positive for hTERT activity resulting in large quantities
of telomeric repeat containing PCR products of increas-
ing length similar to those present in the positive con-
trol (Figure 1D, lanes 2, 3).
To further characterize the BCi-NS1 cells and deter-
mine if they retain characteristics of primary BC, Western
analysis was carried out using antibodies against basal cell
(KRT5, TP63); secretory cell (MUC5AC); Clara cell (CC10);
and ciliated cell (DNAI1) specific markers (Figure 1E). The
basal cell markers were expressed at comparable levels in
the primary BC and BCi-NS1 cells but at higher levels
relative to the bronchial brushing positive control. In con-
trast, the differentiated cell markers (MUC5AC, CC10 and
DNAI1) were only detected in the bronchial brushing and
absent from the primary BC and BCi-NS1 cells. Overall,
these data demonstrate that over-expression of hTERT is
sufficient to extend the lifespan of primary human airway
BC while retaining the morphological characteristics of
the primary cells. We assessed the effect of continuous
culture on cell viability of the BCi-NS1 cells by calculating
the percentage of viable cells using trypan blue exclu-
sion at early and late passages. Comparison of eleven
early passages (passage 8–20) vs eleven later passages
(passage 35–46) showed a significant, but minor, increase
(p < 0.01) in cell viability for later (86.5%) vs early
(80.5%) passages (Additional file 1: Figure S1A). These
data suggest that continuous serial culture of the cells
selects for a population of cells with increased viability.
Isolation of a clonal immortalized human airway basal
cell line
In order to fully characterize the functional properties
of the BCi-NS1 cells, an individual clone, BCi-NS1.1,
was isolated using serial dilution of passage 19 BCi-
NS1 cells. Comparison of the parental (BCi-NS1) and
clonal (BCi-NS1.1) cells at the morphological level
demonstrated both cell types displayed a healthy cob-
ble stone morphology typical for airway BC (Figure 2A
compared to Figure 1C). Western analysis using anti-
bodies against basal cell specific markers (KRT5,
TP63) revealed that the primary BC and the parental
(BCi-NS1) and clonal (BCi-NS1.1) immortalized cells
were positive for both markers (Figure 2B). Immuno-
histochemistry of cytospin slides revealed the BCi-
NS1.1 cells were >99% positive for the basal cells
markers KRT5, TP63 and CD151, but negative for the
differentiated cell markers β-tubulin IV (ciliated cell);
MUC5AC (secretory cell); TFF3 (goblet cell); CC10
(Clara cell); chromogranin A (neuroendocrine cell);




























Figure 1 Isolation and generation of the immortalized human airway basal cell line BCi-NS1. A. Morphology of the parental primary basal
cells at passage 1. B. Morphology of the primary basal cells following senescence at passage 5 of culture. C. Morphology of immortalized basal
cells (BCi-NS1) following passage 13 of culture. D. Telomerase activity of immortalized basal cells (TRAP assay). Lane 1 – Parental primary basal
cells; lane 2 – immortalized basal cells BCi-NS1; lane 3 – positive control (Pos; telomerase positive HeLa cell extract); lane 4 – negative control
(Neg; heat-inactivated telomerase positive HeLa cell extract). E. Characterization of immortalized basal cells by Western analysis of cell type specific
markers. Lane 1 – Primary basal cells; lane 2 – BCi-NS1 immortalized basal cells; and lane 3 – bronchial brushing. For all cells, shown is the
expression of basal cells markers (KRT5, TP63), secretory cell marker (MUC5AC), Clara cell marker (CC10) and ciliated cell marker (DNAI1). GAPDH
was used as a loading control.
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sages (passage 6–23) vs twelve later passages (passage
41–71) showed no significant change (p > 0.4) in cell
viability between early (89.6%) and late (91.4%) pas-
sages (Additional file 1: Figure S1B).
To determine whether hTERT immortalization of hu-
man airway BC induced genetic abnormalities, karyotype
analysis was carried out on passage 9 BCi-NS1.1 cells.
At passage 9, the majority of the cells had a normal male
karyotype (46,XY) with approximately 30% containing
trisomy 20. There were isolated single individual cells
with a single reciprocal translocation as the sole detect-
able abnormality [46,XY,t(15;16)(p12;p11) and 46,XY,t
(6;11)(~p23;q13 ~ 4)]. The presence of heterogeneity in
the BCi-NS1.1 cells suggest that genetic abnormalities
resulting from hTERT immortalization arose early in the
expansion phase of the isolated clone. To assess the pro-
gressiveness of these genetic alterations, we analyzed the
karyotype at a later passage. The results demonstrated
that by passage 35, trisomy 20 was present in approxi-
mately 45% of cells and one of the previous observed
translocations [46,XY,t(15;16)(p12;p11)] was present as a
minor clone (10%). The increase in frequency of trisomy
20 and the single translocation with long term culture
suggest these genetic abnormalities convey a competitivegrowth advantage in culture. A recent study by Tabach
et al. [52] using prostate epithelial cells demonstrated
that hTERT induced immortalization resulted in amplifi-
cation of chromosome 20q13 early in the transformation
process. With increasing passage of the cells, the fre-
quency of trisomy 20q13 increased and positively corre-
lated with the increasing proliferation rate of the cells
with continuing culture. However, analysis of BCi-NS1.1
cells during early (passage 9–12), middle (passage 46–49)
and late (passage 71–74) passages saw no significant dif-
ference (p > 0.25) in proliferation rate of the cells at any
time point with increasing passage (Additional file 1:
Figure S2). Therefore, the proliferative effects of tri-
somy 20 may be cell type specific.
BCi-NS1.1 cell retain the capacity of primary airway basal
cells to secrete VEGFA and cross-talk with endothelial cells
To determine whether immortalization had any deleterious
effects on cellular function, we assessed whether immortal-
ized BCi-NS1.1 cells retain the ability of primary BC to se-
crete vascular endothelial growth factor A (VEGFA) and
proliferate under cytokine- and serum-free conditions dur-
ing co-culture with endothelial cells [50]. The secretion of
VEGFA by primary BC and BCi-NS1.1 cells was assessed
using ELISA (Figure 3A). Growth media exposed to






















Figure 2 Isolation of BCi-NS1.1 clone of the BCi-NS1 immortalized human airway basal cell line. A. Morphology of BCi-NS1.1 clone at
passage 18 and passage 44. B. Comparison of the parental and clonal immortalized basal cells by Western analysis of cell type specific markers.
Lane 1 – Primary basal cells; lane 2 – BCi-NS1 parental immortalized basal cells, passage 24; and lane 3 – BCi-NS1.1 clonal immortalized basal
cells, passage 3. For all cells, shown is the expression of the basal cell markers KRT5 and TP63. GAPDH was used as a loading control.
C. Immunohistochemical characterization of cytopreps of BCi-NS1.1 cells (passage 22) with cell-type specific markers: KRT5 (basal cell);
TP63 (basal cell); CD151 (basal cell); β-tubulin IV (ciliated cell); MUC5AC (secretory cell); TFF3 (goblet cell); CC10 (Clara cell); chromogranin
A (neuroendocrine cell); N-cadherin (mesenchymal cell) and isotype control. Bar = 20 μm.
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and processed as described in Methods. Comparison of
four independent cultures of primary BC and four inde-
pendent passages of BCi-NS1.1 cells revealed primary
BC secrete on average 0.0036 pg/cell/ml of VEGFA,
whereas BCi-NS1.1 cells secrete on average 0.0023 pg/
cell/ml (Figure 3A). There was no statistical significance
between these levels of secreted VEGFA (p > 0.15). The
levels of secreted VEGFA appeared highly variable be-
tween independent primary BC cultures, whereas min-
imal variation was observed in the BCi-NS1.1 cells
between different passages which most likely reflect the
clonality of the cell line. We also assessed the ability
of the BCi-NS1.1 cells to interact and cross-talk
with endothelial cells in a cytokine- and serum-free co-
culture system. Primary BC or BCi-NS1.1 cells were co-cultured with HUVEC-Akt cells (in growth factor nega-
tive media) and proliferation was quantified every two
days. As expected, when cultured alone in the absence
of growth factors, primary BC and BCi-NS1.1 failed to
proliferate over the course of 4 days (data not shown).
However, when co-cultured with HUVEC-Akt cells, at
4 days post-culture, both primary BC and BCi-NS1.1
cell proliferation was observed and the total cell num-
ber increased 16.9-fold and 18.3-fold relative to day 0,
respectively, for each cell type (Figure 3B). No statistical
significance was observed between the endothelial
dependent proliferation of primary BC compared to
BCi-NS1.1 cells at any time point during co-culture
with endothelium (p > 0.9, day 2 and p > 0.3, day 4).
Overall, these data demonstrate that immortalization of


























































B. Co-culture with endothelium
p>0.3
0 2 4
Figure 3 Secretion of VEGFA by immortalized BCi-NS1.1 cells. A. VEGFA levels assessed by ELISA in growth media from primary airway basal
cell cultures (n = 4) and immortalized BCi-NS1.1 cell cultures (n = 4). Secreted VEGFA was normalized to cell number and calculated as pg/cell/ml.
Data shown is the average ± the standard error of n = 4 independent cultures of primary BC and n = 4 independent passages of BC-NS1.1 cells
from passage 10 to 14. Statistics were calculated by a 2-tailed Student’s t test. B. Endothelial cells support the growth of primary airway basal cells
and immortalized BCi-NS1.1 cells in the absence of growth factors. Human primary BC and immortalized BCi-NS1.1 cells were co-cultured with
Akt-activated human umbilical vein endothelial cells (HUVEC-Akt) in cytokine- and serum-free conditions. At the desired time points, cells were
harvested and the GFP-labeled HUVEC-Akt cells was determined as the GFP+VE-cadherin+ population by flow cytometric analysis, and the
GFP-VE-cadherin- population quantified as expanded basal cells. Data shown is the average ± the standard error of n = 3 independent cultures of
primary BC and n = 3 independent passages of BC-NS1.1 cells from passage 5 to 26 compared directly in tandem for each independent
experiment. Statistics were calculated by a 2-tailed Student’s t test.
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teristics of primary BC.BCi-NS1.1 cells retain the differentiation capacity of
primary airway basal cells
As the progenitor cells of the human airway epithelium,
primary BC can be cultured in vitro under differentiating
air-liquid interface (ALI) culture conditions to produce a
fully differentiated mucociliated epithelium [4]. To assess
whether BCi-NS1.1 cells retained the progenitor capacity
of the primary BC, immortalized BCi-NS1.1 cells were cul-
tured under differentiating ALI conditions for 40 days and
the transepithelial electrical resistance (TER), a measure of
tight junction formation, was measured at each media
change from ALI day 10–40 (Figure 4A). The results dem-
onstrated an increase in TER between ALI day 10 (57 ± 4
Ω × cm2) and ALI day 14 (165 ± 67 Ω × cm2) which con-
tinued to increase for the next 14 days until reaching plat-
eau between ALI day 28 (1312 ± 281 Ω × cm2) and ALI
day 40 (1563 ± 86 Ω × cm2). The levels of TER detected
between ALI day 28 to 40 were consistent with those typ-
ical of differentiated primary airway epithelial cells [53,54].
To further characterize the ability of BCi-NS1.1 cells to es-
tablish tight junctions at the molecular level, we assessed
the expression of the tight junction complex genes claudin
3 (CLDN3) and claudin 8 (CLDN8) by TaqMan quantita-
tive PCR during ALI culture. Comparison of ALI day 0 vs
day 28 demonstrated a significant increase in expression of
both genes at ALI day 28 (CLDN3, p < 0.001 and CLDN8,
p < 0.02; Figure 4B). These data further strengthen the
transepithelial resistance data and support the conclusionthat the BCi-NS1.1 cells are capable of polarizing and
forming tight junctions during ALI culture.
Differentiation capacity was then confirmed at the
histological level by analyzing ALI day 28 cross-sections
of BCi-NS1.1 cells which revealed the presence of a
pseudostratified ciliated epithelium (Figure 5A). Im-
munofluorescent staining of the same cross-sections for
KRT5 (basal cell marker) and β-tubulin IV (ciliated cell
marker) demonstrated positive staining for both basal
and ciliated cells at ALI day 28 (Figure 5B). Quantifica-
tion of BCi-NS1.1 differentiation into a mucociliated
epithelium over long-term culture was assessed via
Alcian blue staining of ALI day 28 cross-sections gener-
ated from BCi-NS1.1 cells ranging from passage 6 to 43.
The results demonstrated that, on average, 9.3% ciliated
cells and 3.1% Alcian blue positive secretory cells were
present at ALI day 28 (Figure 5C). Quantification of KRT5
positive cells in adjacent ALI day 28 cross-sections gener-
ated from the same samples by immunofluorescent stain-
ing demonstrated an average of 64.6 ± 2.2% of the total
cells remained positive for the BC specific marker, suggest-
ing a significant proportion of the BCi-NS1.1 cells did not
differentiate (not shown).
The percentage of secretory cells remained relatively
stable with increasing passage number of BCi-NS1.1 cells;
however, for ciliated cells, there appeared to be a reduction
in the capacity of the BCi-NS1.1 cells to differentiate into
this cell type from passage 30 onwards (Figure 5C). The
reduction in capacity to differentiate into ciliated cells may
correspond with the increased presence of cells containing
genetic abnormalities, as demonstrated with the karyotype















Days in ALI culture

































Figure 4 Tight junction formation of immortalized BCi-NS1.1
cells during air-liquid interface culture. A. Transepithelial electric
resistance (TER) of BCi-NS1.1 cells cultured on air-liquid interface
(ALI). Resistance (Ohms x cm2) was measured at every media
change. Data shown is the average TER ± the standard error of n = 8
independent experiments from passage 6–30 cells between day 10
to 40 of ALI culture. B. Expression of tight junction-related genes of
BCi-NS1.1 cells. At ALI day 0 and day 28, TaqMan quantitative PCR
analysis was used to assess expression of the tight junction related
genes claudin 3 (CLDN3) and claudin 8 (CLDN8). Data shown is the
average ± the standard error of n = 10 independent experiments for
BC-NS1.1 cells from passage 6 to 43. Statistics were calculated by a
2-tailed Student’s t test.
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http://respiratory-research.com/content/14/1/135differentiation results are obtained from single independ-
ent experiments at each passage and therefore, additional
experiments are required to confirm this observation and
whether or not the increase in genetic instability is the de-
termining factor. To compare the differentiation capacity
of primary BC and BCi-NS1.1 cells, nonsmoker primary
BC were cultured on ALI for 28 days and differentiation
into a mucociliated epithelium assessed as described
above for BCi-NS1.1 cells. The results demonstrated a
significant decrease in the number of ciliated cells for
the BCi-NS1.1 cells vs primary BC cultures (9.3 vs
32.9%, p < 0.007); however, there were no significant dif-
ferences in the number of Alcian blue positive secretory
cells in the BCi-NS1.1 cells vs primary BC cultures
(3.1 vs 4.0%, p > 0.05; Figure 5D). Overall, these data
demonstrate that immortalized BCi-NS1.1 cells are cap-
able of establishing tight junctions and differentiatinginto a pseudostratified mucociliated epithelium follow-
ing long-term ALI culture.
Multipotent differentiation capacity of BCi-NS1.1 and
primary airway basal cells
To further characterize the differentiation capacity of the
BCi-NS1.1 cells during ALI culture compared with that
observed with primary BC, TaqMan quantitative PCR,
Western analysis and immunofluorescent staining using
cell type specific markers were undertaken. TaqMan ana-
lysis of the primary BC using cell type specific transcript
primer-probesets demonstrated multipotent differentiation
capacity of the cells (Figure 6A). Comparison of ALI day 0
vs day 28 for expression of the BC markers KRT5 and
TP63 revealed a significant decrease in expression of each
gene at day 28 compared to day 0 (KRT5, p < 0.005 and
TP63, p < 0.005), suggesting differentiation of the BC into
additional cell types. In contrast, secretory cell markers
(MUC5AC and MUC5B) and ciliated cell markers (DNAI1
and FOXJ1) were negative at ALI day 0 but readily detected
at ALI day 28, confirming differentiation of the BC into the
secretory and ciliated cell types. Analysis of both TFF3
(goblet cell marker) and CC10 (Clara cell marker) revealed
a low level of expression at ALI day 0; however, a significant
increase in expression was observed at ALI day 28 (TFF3,
p < 0.03; CC10, p < 0.04), demonstrating the primary BC
can differentiate into both the goblet and Clara cell types.
Analysis of the BCi-NS1.1 cells cultured under identical
conditions to that of the primary BC demonstrated similar
results (Figure 6B). As observed for the primary BC, com-
parison of ALI day 0 vs day 28 from BCi-NS1.1 cells for
expression of the BC markers KRT5 and TP63 revealed a
significant decrease in expression of each gene at day 28
compared to day 0 (KRT5, p < 0.002 and TP63, p < 0.02).
Similarly to primary BC, secretory cell markers (MUC5AC
and MUC5B) and ciliated cell markers (DNAI1 and
FOXJ1) were negative at ALI day 0 but readily detected at
ALI day 28, confirming differentiation of the BCi-NS1.1
cells into the secretory and ciliated cell types. For both
TFF3 (goblet cell marker) and CC10 (Clara cell marker),
low levels of expression at ALI day 0 were detected; how-
ever, like primary BC, a significant increase in expression
was observed at ALI day 28 (TFF3, p < 0.001; CC10, p <
0.05), demonstrating BCi-NS1.1 cells can differentiate into
both goblet and Clara cells.
Western analysis of primary BC comparing day 0
(Figure 6C, lane 1) and day 28 (Figure 6C, lane 2)
demonstrated expression of the basal cell marker TP63
at both time points, with a reduction in levels at ALI
Day 28, while Clara (CC10) and ciliated (DNAI1,
FOXJ1) cell markers were only detected at ALI day 28
(Figure 6C). Analysis of BCi-NS1.1 cells revealed iden-
tical expression patterns at day 0 (lane 3) and day 28
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A. H&E, ALI day 28 B. Immunofluorescence, ALI day 28
KRT5 DAPI -tubulin IV
Figure 5 Differentiation capacity of immortalized BCi-NS1.1 cells over long-term culture. A. Morphology of ALI day 28 of BCi-NS1.1 cells,
passage 30 demonstrating a multilayer ciliated epithelium, hematoxylin and eosin staining B. Immunofluorescent staining of ALI day 28 of
BCi-NS1.1 cells, passage 30, for KRT5 (basal cell, red), β-tubulin IV (ciliated cell, green) and nuclei (blue). A, B. Bar = 20 μm. C. Quantification of
differentiation of ALI day 28 cross-sections of BCi-NS1.1 cells. The number of positive ciliated and secretory cells was scored for BCi-NS1.1 cells for
n = 10 independent experiments from cells between passage 6 to 43. The data is presented for each cell type as percentage relative to the total
number of cells. In addition, the average ± the standard error of n = 10 independent experiments is shown. D. Comparison of the differentiation
capacity of BCi-NS1 cells to that of primary airway BC. Primary BC were cultured under identical differentiation-inducing conditions on ALI to that
of BCi-NS1.1 cells and quantified in an identical manner. The number of positive ciliated and secretory cells was scored for primary BC and
presented for each cell type as percentage relative to the total number of cells. The average ± the standard error of n = 5 independent experiments is
shown and compared to the average data for BCi-NS1.1 described in panel C. Statistics were calculated by a 2-tailed Student’s t test.
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http://respiratory-research.com/content/14/1/135staining of CC10 (Clara), MUC5AC (secretory) and
TFF3 (goblet) revealed positivity for all these cells types
in ALI day 28 cultures of primary BC and BCi-NS1.1 cells
(Figure 6D-F).
Overall, these data demonstrate that both primary BC
and immortalized BCi-NS1.1 cells have multipotent dif-
ferentiation capacity and are capable of differentiating
into the secretory, goblet, Clara and ciliated cell types
during in vitro ALI culture.
IL-13 modulation of differentiation of BCi-NS1.1 cells
Dysregulation of the progenitor function of primary air-
way BC by cytokine exposure plays an important role inmediating the pathology associated with respiratory dis-
eases characterized by airway remodeling, including
asthma and COPD [8,26,28-30]. One such cytokine is
interleukin-13 (IL-13), a known mediator of regulating
mucus metaplasia and mucin production, and capable of
increasing secretory cell differentiation of primary nor-
mal human bronchial epithelium in vitro [53,55,56].
BCi-NS1.1 cells were cultured on ALI and at ALI day
10, exposed to IL-13 until harvest at ALI day 28 for
analysis of differentiation. Measurement of the TER at
ALI day 28 demonstrated a significant decrease in epi-
thelial resistance in IL-13 treated cells relative to un-
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Figure 6 (See legend on next page.)
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(See figure on previous page.)
Figure 6 Comparison of the differentiation capacity of immortalized BCi-NS1 cells to that of primary basal cells. Primary airway BC and
immortalized BCi-NS1 cells were cultured under differentiation inducing conditions on air-liquid interface (ALI). A, B. mRNA transcripts; A. Primary
BC. B. BCi-NS1.1 cells. At ALI day 0 and day 28, TaqMan quantitative PCR analysis was used to assess cell type specific mRNA markers: KRT5 (basal
cell); TP63 (basal cell); MUC5AC (secretory cell); MUC5B (secretory cell); TFF3 (goblet cell); CC10 (Clara cell); DNAI1 (ciliated cell) and FOXJ1 (ciliated
cell). Data shown is the average ± the standard error of n = 5 independent experiments for primary BC and n = 10 independent experiments for
BC-NS1.1 cells. Statistics were calculated by a 2-tailed Student’s t test. Asterisk (*) indicates not detected. For B, the data represents an average ±
the standard error for BCi-NS1.1 cells from passage 6 to 43. C. Characterization of differentiation by Western analysis of cell type specific markers.
Lane 1 – Primary BC, ALI day 0; lane 2 – Primary BC, ALI day 28; lane 3 – BCi-NS1.1, ALI day 0; and lane 4 – BCi-NS1.1, ALI day 28. Shown is the
expression of a basal cell marker (TP63); Clara cell marker (CC10); and ciliated cell markers (DNAI1 and FOXJ1). GAPDH was used as a loading
control. D,E,F. Immunofluorescent staining of ALI day 28 primary BC and BCi-NS1.1 cells for D. CC10 (Clara cell, red), E. MUC5AC (secretory cell,
green) or F. TFF3 (goblet cell, red) and nuclei (blue). Bar = 20 μm. For C-F all data shown is representative of n = 3 independent experiments.
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http://respiratory-research.com/content/14/1/135suggesting disordering of BCi-NS1.1 differentiation. This
was confirmed at the histological level via Alcian blue
staining of ALI day 28 cross-sections of untreated and
IL-13 stimulated BCi-NS1.1 cells (Figure 7B). Quantifi-
cation of these changes demonstrated a significant de-
crease in the number of ciliated cells for the IL-13
treated vs untreated cultures (10.9 vs 5.8%, p < 0.04) with
a reciprocal increased number of Alcian blue positive
secretory cells in the IL-13 treated vs untreated cultures
(2.6 vs 18.5%, p < 0.003; Figure 7C).
To further characterize the effects of IL-13 on the differ-
entiation capacity of the BCi-NS1.1 cells, TaqMan quantita-
tive PCR, Western analysis and immunofluorescent
staining using cell type specific markers were assessed. Taq-
Man analysis of ALI day 28 untreated vs IL-13 stimulated
cells with cell type specific transcript primer-probesets
demonstrated significant differences in expression of a sub-
set of cell type specific markers (Figure 8A). Analysis of the
BC markers KRT5 (p > 0.7) and TP63 (p > 0.9) revealed no
significant changes in expression upon stimulation with
IL-13. For the secretory cell marker MUC5AC (p < 0.04)
and goblet cell marker TFF3 (p < 0.02) there was a signifi-
cant increase in expression upon IL-13 stimulation, but no
significant changes were observed for the secretory cell
marker MUC5B (p > 0.5). In contrast to MUC5AC and
TFF3, there was a significant decrease in expression of the
Clara cell marker CC10 (p < 0.04) and ciliated cell markers
DNAI1 (p < 0.02) and FOXJ1 (p < 0.03) in IL-13 stimulated
vs untreated cells. These data were validated at the protein
level by Western analysis and immunofluorescent staining.
Western analysis of untreated (Figure 8B, lane 1) and IL-13
stimulated (lane 2) ALI day 28 BCi-NS1.1 cells demon-
strated equal expression of the basal cell markers KRT5
and TP63. However, levels of Clara (CC10) and ciliated
(DNAI1 and FOXJ1) cell markers were decreased in the
IL-13 stimulated cells. Immunofluorescent staining of
MUC5AC (secretory) revealed increased percentage of
positive cells in IL-13 stimulated vs untreated BCi-NS1.1
cells (Figure 8C). Overall, these data demonstrate that the
differentiation potential of ALI cultures of BCi-NS1.1 cells
can be altered by exposure to specific stimuli known to play
a role in mediating the pathology of respiratory diseases.BCi-NS1.1 cell retain the capacity to repair injured areas
of the epithelium
We next assessed the ability of the BCi-NS1.1 cells to re-
spond to mechanical damage during ALI culture by per-
forming simple scratch and wound healing assays
(Figure 9). The results demonstrated that BCi-NS1.1 cells
were capable of repairing the wounded area within 20 hr
when assessed at all ALI time points (day 0, 7, 14, 21 and
28), suggesting that repair processes, including the re-
quired synthesis and secretion of basal lamina matrices,
are maintained with immortalization. Comparable results
were obtained with the parental immortalized BCi-NS1
cells at early time points (ALI day 0 and 7); however,
around ALI day 10–14, the cells spontaneously began to
leak and lose integrity which prevented their analysis at
later time points (not shown).
Discussion
Basal cells function as multipotent stem/progenitor cells
of the mouse and human airway epithelium, capable of
differentiating into the specialized cell populations of the
mucociliated airway epithelium [4-18]. The focus of this
study was to establish an immortalized normal human air-
way BC cell line capable of replicating long-term and
retaining characteristics of primary BC. Primary human air-
way BC isolated from the airway epithelium of a healthy
nonsmoker were successfully immortalized via retrovirus-
mediated expression of hTERT to create the cell line basal
cell immortalized-nonsmoker 1 (BCi-NS1). A clonal de-
rived population (BCi-NS1.1) retains characteristics of pri-
mary BC for over 40 passages including secretion of
VEGFA, interaction with endothelial cells, ability to actively
repair wounded areas of the epithelium and multipotent
differentiation capacity on air-liquid interface (ALI) cul-
ture with differentiation into secretory, goblet, Clara
and ciliated cells. Importantly, these cells respond to
external stimuli such as IL-13, resulting in alteration of
the normal differentiation process.
Primary human airway BC are positive for the pan-BC
markers KRT5 and TP63, with subpopulations that
demonstrate positivity for additional markers including
KRT14, CD151, NGFR and ITGA6 [4-7,11]. The clonal
B. Morphology, Alcian blue staining
IL-13
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Figure 7 IL-13 modulation of differentiation of BCi-NS1.1 immortalized airway basal cells. BCi-NS1.1 cells were cultured under differentiation
inducing conditions on air-liquid interface (ALI) in the absence and presence of IL-13. A. Transepithelial electric resistance (TER) of the airway epithelia
in the absence and presence of IL-13. The resistance (Ohms x cm2) was measured at ALI day 28. Data is presented as the percentage resistance relative
to untreated cells and plotted as the average ± the standard error of n = 5 independent experiments (BCi-NS1.1, passage 6–15). B. Morphology of
untreated and IL-13 treated cells. Alcian blue staining of ALI day 28 sections of BCi-NS1.1 cells untreated or treated with IL-13. Bar = 20 μm.
C. Quantification of differentiation. Shown is Alcian blue staining of ALI day 28 sections of BCi-NS1.1 cells untreated or treated with IL-13. The number
of positive ciliated and secretory cells scored. Data is presented for each cell type as percentage relative to the total number of cells. Data shown is the
average ± the standard error of n = 5 independent experiments (BCi-NS1.1, passage 6–15). All statistics were calculated by a 2-tailed Student’s t test.
Walters et al. Respiratory Research 2013, 14:135 Page 14 of 18
http://respiratory-research.com/content/14/1/135immortalized BCi-NS1.1 cell line was positive for KRT5,
TP63 and CD151. When placed on ALI on type IV col-
lagen, BCi-NS1.1 cells were capable of establishing high
levels of transepithelial electrical resistance, and like
primary BC, differentiated into all cell types of theconducting airway. In addition, stimulation of BCi-
NS1.1 cells during ALI culture with IL-13, a cytokine
known to play an important role in the pathology of
asthma and COPD in vivo, resulted in alteration of the
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Figure 8 Quantification of IL-13 modulation of the differentiation of BCi-NS1.1 immortalized airway basal cells. BCi-NS1.1 cells were
cultured on air-liquid interface (ALI) in the absence and presence of IL-13. A. TaqMan analysis of cell type specific mRNA markers at ALI day 28,
including basal cell markers (KRT5, TP63); secretory cell markers (MUC5AC, MUC5B); goblet cell marker (TFF3); Clara cell marker (CC10); and ciliated cell
markers (DNAI1, FOXJ1). Data shown is the average ± the standard error of n = 5 independent experiments (BCi-NS1.1, passage 6–15). Statistics were
calculated by 2-tailed Student’s t test. U = untreated; IL-13 = treated with IL-13. B. Western analysis of untreated and IL-13 treated cells of cell type
specific markers at ALI day 28. Lane 1 – untreated, lane 2 – IL-13 treated. Shown is the expression of a basal cell marker (TP63); Clara cell marker (CC10)
and ciliated cell markers (DNAI1, FOXJ1). GAPDH was used as a loading control. C. Immunofluorescent staining of ALI day 28 membranes for untreated
and IL-13 treated cells for MUC5AC (secretory cell, green) and nuclei (blue). Bar = 20 μm. For B and C, all data shown is representative of n = 3
independent experiments.
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corresponding decrease in Clara and ciliated cell differen-
tiation consistent with previous studies using cultures of
primary normal bronchial epithelial cells [53,55,56]. The
resulting alteration in BCi-NS1.1 differentiation produce a
remodeled in vitro pseudostratified epithelium reminiscent
of that observed in vivo in asthma and COPD
[8,26,28-30], demonstrating the potential use of this cell
line in understanding the mechanisms by which environ-
mental stimuli play a central role in the pathology of clin-
ically relevant airway disease.
Long term cultures of immortalized normal human
bronchial epithelium have previously been generated from
bronchial-derived donor material using a number ofdifferent methods, including adenovirus-SV40 hybrid
virus; plasmid containing replication defective SV40 virus
genome; plasmid or retroviral gene transfer-mediated de-
livery of viral oncoproteins (HPV-16 E6 and E7, or SV40
T-antigen) alone or together with hTERT, or expression of
hTERT alone or in combination with CDK4 or Bmi-1
(Additional file 1: Table S1). These established cell lines
have an extended lifespan far beyond the primary cells
from which they were derived and retain some capacity to
differentiate into other specialized cells of the airway epi-
thelium. For example, BEAS-2B cells, which were devel-
oped by immortalization of normal human bronchial
epithelial cells using an adenovirus-SV40 hybrid virus, re-
tain the capacity for squamous differentiation, while
ALI day 0





Figure 9 Wound healing capacity of immortalized BCi-NS1.1
cells. BCi-NS1.1 cells were cultured on air-liquid interface (ALI)
culture and the ability of the cells to repair injury to the epithelium
assessed at ALI day 0, 7, 14, 21 and 28. Images were obtained at the
time of injury (t = 0) and 20 hr later (t = 20) once repair had taken
place. All data shown is representative of n = 5 independent
experiments using BCi-NS1.1 cells between passage 7 to 44.
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plasmid containing a replication deficient SV40 virus gen-
ome) can differentiate into ciliated cells in ALI culture
[35,41,57]. Similarly, immortalizing bronchial epithelial
cells using HPV-16 E6 and E7 alone (VA10 cells) or to-
gether with hTERT (NuLi 1–2) resulted in cell lines cap-
able of differentiating into ciliated (VA10) or ciliated and
goblet cells (NuLi-2) on ALI culture [39,40,58]. Combined
expression of SV40 early antigen and hTERT resulted in
immortalization of small airway epithelial cells to generate
the cell line SA (SV40 ER + hTERT) which, when injected
subcutaneously into a nude mouse, produced airway
epithelium with normal histology [38]. The alternative
strategy of immortalization in the absence of viral onco-
proteins resulted in the generation of cell lines with differ-
entiation capacity. Combined expression of hTERT and
CDK4, allowed for the generation of the HBEC3 cell linethat differentiates into a mucociliated epithelium during
ALI when cultured on a fibroblast containing collagen gel
[42]. Submerged 2D culture of these cells in defined differ-
entiation media resulted in simultaneous expression of
both basal, Clara and type II pneumocyte markers [59-61].
A similar strategy using combined expression of
hTERT and Bmi-1 resulted in generation of the
UNCN1T, 2 T and 3 T cell lines that retained the ability
to differentiate into a pseudostratified epithelium with
ciliated and secretory cells [46].
The differences in differentiation capacity observed be-
tween the cell lines may be explained by a number of fac-
tors, including the immortalization strategy utilized and
the culture conditions used to analyze differentiation. The
different origins and source of primary cells used in each
study may be an equally important factor. In the present
study, the primary BC donor material for establishing the
immortalized BCi-NS1.1 cells was obtained by bronchial
brushing of a healthy nonsmoker, whereas the donor ma-
terial used in previous studies was from bronchial derived
explants; autopsy specimens; lung transplants; bronchial
epithelium; or commercially available sources (Additional
file 1: Table S1). Characterization of the HBEC3 and VA10
cell lines demonstrate they express BC markers (HBEC3:
TP63+KRT14+ and VA10: TP63+KRT5+KRT14+), suggest-
ing the primary cells from which they were derived were
of BC origin [40,61]. In addition to the potential role of
the source of donor material on differentiation capacity of
the generated immortalized cell lines, it may also have a
significant impact on the efficiency of different strategies
used to immortalize the cells. For instance, Ramirez et al.
[42] demonstrated that both hTERT and CDK4 were re-
quired to immortalize airway epithelial cells. However, our
results and those of Piao et al. [43] demonstrated that
hTERT alone was sufficient. The use of different donor
materials between each study may result in different sub-
populations of primary epithelial cells at the time of
immortalization which may have different requirements
for immortalization.
Recent studies have demonstrated that primary
human epithelial cells (including human airway epithe-
lium) can be propagated indefinitely in vitro when co-
cultured with irradiated fibroblast feeder cells and a Rho
kinase inhibitor [33,34]. These cultured cells are termed
conditionally reprogrammed cells (CRCs), as removal of
the reprogramming conditions allows the cells to differen-
tiate in a tissue-specific manner. One major advantage of
this system over generating immortalized cell lines is that
the CRC’s are karyotype stable, thus allowing cell biology
studies without the potential negative effects of using gen-
etically unstable cell cultures. However, the more complex
culture system, potential variability between clinical donor
material, and expensive costs of acquiring primary cells
may prevent rapid adoption of this technology. In the
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derived cell lines provide a viable alternative.
Conclusion
Basal cells have a central role in homeostasis and regen-
eration of the normal airway epithelium following injury
or insult by environmental insult, including smoking
and inflammatory cytokines [4-18]. Importantly, airway
BC contribute to the pathogenesis of diseases character-
ized by airway epithelial remodeling, including COPD
and asthma, and the biology of the malignant trans-
formation of the epithelium into bronchogenic carcin-
oma [8,19-30]. The BCi-NS1.1 cells, together with other
immortalized BC cell lines, provide cell populations to
help understand the mechanisms by which the differen-
tiation capacity of the BC is regulated, and how the cells
respond to specific environmental stimuli is central to
the understanding of these diseases. Finally, the ability
to isolate primary BC from individuals by broncho-
scopic brushing and subsequently immortalize them
provides a strategy to deriving patient specific BC cell
lines that can be used to study the effect of specific gen-
etic variants on BC differentiation under normal condi-
tions or in response to specific environmental stimuli,
including cytokines or cigarette smoke.
The BCi-NS1.1 cell line is available for use by investi-
gators (geneticmedicine@med.cornell.edu).Additional file
Additional file 1: Table S1. Summary of immortalized human airway
epithelial cell lines. Figure S1. Cell viability analysis of parental and clonal
immortalized BCi-NS1 cells over continuous serial passage. Figure S2.
Growth rate analysis of immortalized BCi-NS1.1 following extended
serial passage.
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